Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Large Increase in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 179,400 shares, a growth of 60.5% from the October 15th total of 111,800 shares. Approximately 19.1% of the shares of the stock are short sold. Based on an average trading volume of 554,000 shares, the days-to-cover ratio is presently 0.3 days.

Allarity Therapeutics Stock Down 4.8 %

NASDAQ ALLR traded down $0.07 on Friday, hitting $1.34. 305,517 shares of the company were exchanged, compared to its average volume of 254,030. Allarity Therapeutics has a 1-year low of $1.26 and a 1-year high of $666.00. The firm has a 50 day moving average of $1.99 and a two-hundred day moving average of $8.43.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.